A phase 3 randomized trial comparing inolimomab vs usual care in steroid-resistant acute GVHD.

Treatment of steroid-resistant acute graft-versus-host disease (GVHD) remains an unmet clinical need. Inolimomab, a monoclonal antibody to CD25, has shown encouraging results in phase 2 trials. This phase 3 randomized, open-label, multicenter trial compared inolimomab vs usual care in adult patients with steroid-refractory acute GVHD. Patients were randomly selected to receive treatment with inolimomab or usual care (the control group was treated with antithymocyte globulin [ATG]). The primary objective was to evaluate overall survival at 1 year without changing baseline allocated therapy. A total of 100 patients were randomly placed: 49 patients in the inolimomab arm and 51 patients in the ATG arm. The primary criteria were reached by 14 patients (28.5%) in the inolimomab and 11 patients (21.5%) in the ATG arms, with a hazard ratio of 0.874 (P = .28). With a minimum follow-up of 1 year, 26 (53%) and 31 (60%) patients died in the inolimomab and ATG arms, respectively. Adverse events were similar in the 2 arms, with fewer viral infections in the inolimomab arm compared with the ATG arm. The primary end point of this randomized phase 3 trial was not achieved. The lack of a statistically significant effect confirms the need for development of more effective treatments for acute GVHD. This trial is registered to https://www.clinicaltrialsregister.eu/ctr-search/search as EUDRACT 2007-005009-24.

[1]  F. Guilhot,et al.  Long-term follow-up of corticosteroid refractory acute GVHD treated with an Inolimomab-based algorithm: a single center experience , 2013, Bone Marrow Transplantation.

[2]  J. Wingard,et al.  First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[3]  R. Porcher,et al.  Steroid-refractory acute GVHD: lack of long-term improved survival using new generation anticytokine treatment. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[4]  E. Shpall,et al.  Steroid-Refractory Acute GVHD: Predictors and Outcomes , 2011, Advances in hematology.

[5]  A. Busca The use of monoclonal antibodies for the treatment of graft-versus-host disease following allogeneic stem cell transplantation , 2011, Expert opinion on biological therapy.

[6]  R. Porcher,et al.  Initial Liver Involvement in Acute GVHD is Predictive for Nonrelapse Mortality , 2009, Transplantation.

[7]  G. Dini,et al.  Daclizumab as useful treatment in refractory acute GVHD: a paediatric experience , 2009, Bone Marrow Transplantation.

[8]  B. Blazar,et al.  Acute graft-versus-host disease: from the bench to the bedside. , 2005, Blood.

[9]  E. Holler,et al.  Graft-versus-host disease , 2009, The Lancet.

[10]  H. Deeg,et al.  How I treat refractory acute GVHD. , 2007, Blood.

[11]  H. Deeg,et al.  A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. , 2007, Blood.

[12]  J. Briones,et al.  Encouraging results with inolimomab (anti-IL-2 receptor) as treatment for refractory acute graft-versus-host disease. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[13]  A. Bacigalupo,et al.  Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. , 2006, Blood.

[14]  A. Fischer,et al.  Inolimomab in Steroid-Refractory Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation: Retrospective Analysis and Comparison with Other Interleukin-2 Receptor Antibodies , 2005, Transplantation.

[15]  E. Holler,et al.  Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept , 2005, Bone Marrow Transplantation.

[16]  S. Farag,et al.  Monoclonal antibodies for the prevention and treatment of graft-versus-host disease. , 2003, Seminars in oncology.

[17]  J. Wagner,et al.  Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[18]  M. Remberger,et al.  Treatment of severe acute graft‐versus‐host disease with anti‐thymocyte globulin , 2001, Clinical transplantation.

[19]  C. Currie,et al.  Treatment of steroid-resistant acute graft-versus-host disease with rabbit antithymocyte globulin. , 2000, Journal of hematotherapy & stem cell research.

[20]  D. Mclellan,et al.  Graft-versus-host disease in allogeneic bone marrow transplantation: the role of monoclonal antibodies in prevention and treatment. , 2000, British journal of biomedical science.

[21]  S. Burdach,et al.  Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody. A multicenter phase III study. , 1995 .

[22]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[23]  A. Fischer,et al.  Treatment of steroid-resistant acute graft-versus-host disease with an anti-IL-2-receptor monoclonal antibody (BT 563) in children who received T cell-depleted, partially matched, related bone marrow transplants. , 1994, Bone marrow transplantation.

[24]  J. Bergerat,et al.  Treatment of corticosteroid resistant acute graft-versus-host disease by in vivo administration of anti-interleukin-2 receptor monoclonal antibody (B-B10) , 1990, Blood.

[25]  H. Deeg,et al.  Murine monoclonal anti-T cell antibodies for treatment of steroid-resistant acute graft-versus-host disease. , 1984, Human immunology.